Seres Therapeutics, Inc. MCRB

MCRB Company Overview

Seres Therapeutics, Inc. is a biotechnology company focused on developing and commercializing microbiome therapeutics designed to treat diseases associated with disruptions to the human microbiome. The company operates primarily within the biotechnology and pharmaceutical industries, with a concentration on live biotherapeutic products intended to modulate the composition and function of the microbiome. Seres became widely known for developing microbiome-based therapeutics targeting recurrent bacterial infections and inflammatory diseases. Its principal revenue drivers have historically included collaboration agreements, licensing arrangements, milestone payments, and commercialization-related activities tied to microbiome therapeutics.

The company’s lead commercial product has been VOWST, an orally administered microbiota-based therapeutic approved in the United States for the prevention of recurrence of Clostridioides difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI. Seres has also pursued pipeline programs in gastrointestinal, infectious, metabolic, and immunologic diseases. The company was founded in 2010 and evolved from an early-stage microbiome research platform into a publicly traded biotechnology company listed on Nasdaq under the ticker MCRB. Its strategic positioning has centered on proprietary microbial consortia design, manufacturing capabilities for live biotherapeutics, and clinical development expertise in microbiome medicine.